Portfolio Sync Solutions
Streamline your investment strategy with our portfolio synchronization tools. Seamlessly manage and track your holdings across platforms for enhanced
GET STARTEDVolitionRx Limited Analyst EPS Estimates
| Quarter | Number of Estimates | Low Estimate | High Estimate | Average Estimate |
|---|---|---|---|---|
| Q1 2025 | 1 | -$0.02 | -$0.02 | -$0.02 |
| Q2 2025 | 1 | -$0.02 | -$0.02 | -$0.02 |
| Q3 2025 | 1 | -$0.02 | -$0.02 | -$0.02 |
| Q4 2025 | 1 | -$0.02 | -$0.02 | -$0.02 |
| Q1 2026 | 1 | $0.02 | $0.02 | $0.02 |
| Q2 2026 | 1 | $0.02 | $0.02 | $0.02 |
| Q3 2026 | 1 | $0.02 | $0.02 | $0.02 |
| Q4 2026 | 1 | $0.02 | $0.02 | $0.02 |
| Q1 2027 | 1 | $0.38 | $0.38 | $0.38 |
| Q2 2027 | 1 | $0.38 | $0.38 | $0.38 |
| Q3 2027 | 1 | $0.39 | $0.39 | $0.39 |
| Q4 2027 | 1 | $0.41 | $0.41 | $0.41 |
| Q1 2028 | 1 | $0.52 | $0.52 | $0.52 |
| Q2 2028 | 1 | $0.52 | $0.52 | $0.52 |
| Q3 2028 | 1 | $0.53 | $0.53 | $0.53 |
| Q4 2028 | 1 | $0.56 | $0.56 | $0.56 |
VolitionRx Limited Earnings Date And Information
VolitionRx Limited last posted its earnings results on Monday, March 31st, 2025. The company reported $-0.06 earnings per share for the quarter, missing analysts' consensus estimates of $-0.06 by $0. The company had revenue of 474,522 for the quarter and had revenue of 1.23 M for the year. VolitionRx Limited has generated $0 earnings per share over the last year ($-0.31 diluted earnings per share) and currently has a price-to-earnings ratio of -1.64. VolitionRx Limited has not formally confirmed its next earnings publication date, but the company's estimated earnings date is Monday, May 12th, 2025 based on prior year's report dates.
VolitionRx Limited Earnings History by Quarter
| Date | Quarter | Consensus Estimate | Reported EPS | Beat/Miss | Revenue Estimate | Actual Revenue |
|---|---|---|---|---|---|---|
| 11/14/2024 | Q3 2024 | -$0.07 | -$0.07 | 0 | $652,000 | $474,522 |
| 08/14/2024 | Q2 2024 | -$0.09 | -$0.08 | 0.01 | $462,978 | $395,797 |
| 05/13/2024 | Q1 2024 | -$0.11 | -$0.10 | 0.01 | $589,517 | $171,535 |
| 03/25/2024 | Q4 2023 | -$0.11 | -$0.11 | 0 | $466,667 | $243,973 |
| 11/14/2023 | Q3 2023 | -$0.12 | -$0.11 | 0.01 | $356,600 | $165,211 |
| 08/14/2023 | Q2 2023 | -$0.13 | -$0.14 | -0.01 | $271,250 | $216,310 |
| 05/10/2023 | Q1 2023 | -$0.14 | -$0.15 | -0.01 | $417,750 | $149,808 |
| 03/15/2023 | Q4 2022 | -$0.15 | -$0.13 | 0.02 | $179,800 | $119,715 |
| 11/14/2022 | Q3 2022 | -$0.15 | -$0.14 | 0.01 | $94,335 | $32,714 |
| 08/10/2022 | Q2 2022 | -$0.15 | -$0.14 | 0.01 | $110,750 | $39,752 |
| 05/11/2022 | Q1 2022 | -$0.01 | -$0.14 | -0.13 | $10.02 M | $114,211 |
| 03/30/2022 | Q4 2021 | -$0.14 | -$0.15 | -0.01 | $16,219 | $14,240 |
| 11/10/2021 | Q3 2021 | -$0.10 | -$0.13 | -0.03 | $143,600 | $25,483 |
| 08/11/2021 | Q2 2021 | -$0.12 | -$0.10 | 0.02 | $74,250 | $24,782 |
| 05/11/2021 | Q1 2021 | -$0.12 | -$0.12 | 0 | $8,333 | $25,530 |
| 03/22/2021 | Q4 2020 | -$0.10 | -$0.11 | -0.01 | $3,940 | $7,120 |
| 11/12/2020 | Q3 2020 | -$0.11 | -$0.09 | 0.02 | $2,500 | $575 |
| 08/13/2020 | Q2 2020 | -$0.13 | -$0.12 | 0.01 | $30,000 | $5,194 |
| 05/07/2020 | Q1 2020 | -$0.10 | -$0.14 | -0.04 | $385 | $544 |
| 02/20/2020 | Q4 2019 | -$0.11 | -$0.09 | 0.02 | $12,000 | $0 |
Explore Related Stocks for Market Trends
Explore our related stocks for the latest market trends and stock news to stay informed and make better decisions.
VolitionRx Limited Earnings: FAQ's
VolitionRx Limited has not confirmed its next earnings publication date, but the company's estimated earnings date is Monday, May 12th, 2025 based offlast year's report dates.
The conference call for VolitionRx Limited's latest earnings report can be listened to online.
The conference call transcript for VolitionRx Limited's latest earnings report can be read online.
VolitionRx Limited (:VNRX) has a recorded annual revenue of $1.23 M.
VolitionRx Limited (:VNRX) has a recorded net income of $-26,967,836.VolitionRx Limited has generated $-0.31 earnings per share over the last four quarters.
VolitionRx Limited (:VNRX) has a price-to-earnings ratio of -1.64 and price/earnings-to-growth ratio is -0.16.